Side-by-side comparison of AI visibility scores, market position, and capabilities
Seres Therapeutics develops microbiome therapeutics, including Vowst, the first FDA-approved oral microbiome medicine for preventing recurrent C. difficile infection.
Seres Therapeutics is a publicly traded clinical-stage biopharmaceutical company founded in 2012 that pioneered the development of microbiome therapeutics, medicines derived from human gut microbiota. The company's lead product Vowst received FDA approval in 2023 as the first oral microbiome therapeutic, consisting of purified fecal microbiota spores administered as capsules to prevent recurrent Clostridioides difficile infection after antibiotic treatment. C. difficile infects hundreds of thousands of Americans annually and has high recurrence rates that existing antibiotics cannot fully prevent. Vowst works by restoring a diverse, healthy gut microbiome that can resist C. difficile colonization. Seres has partnered with Nestlé Health Science for US commercialization and is developing pipeline programs for inflammatory bowel disease, oncology supportive care, and other conditions where the gut microbiome plays a pathological role. The company's success with Vowst validated the regulatory pathway for microbiome therapeutics and established Seres as the pioneer of an emerging therapeutic class with broad potential across gastrointestinal and systemic diseases.
Adobe's generative AI suite with commercially-safe Image Model 5 (4MP photorealism), video editor, and audio tools; integrated partner models like FLUX.2 and GPT Image
Adobe Firefly is Adobe's generative AI platform and suite of creative AI tools, launched in March 2023 as Adobe's flagship response to the generative AI revolution. Firefly was purpose-built to be commercially safe — trained exclusively on Adobe Stock images, openly licensed content, and public domain material rather than scraped web data, addressing a core concern that had made competing generative AI tools risky for professional and enterprise creative use. This positioning allowed Adobe to offer content credentials and indemnification for Firefly outputs, making it the enterprise-safe choice for brands and agencies with legal exposure concerns around AI-generated content.\n\nFirefly's capabilities span multiple creative modalities integrated across Adobe's Creative Cloud suite. Image Model 5 generates photorealistic images at 4 megapixel resolution with precise adherence to reference styles and composition guides. Firefly Video enables AI-powered video editing and generation within Premiere Pro, including object removal, scene extension, and text-to-video features. Firefly Audio tools bring generative AI to sound design and audio editing within Audition. Adobe has also launched a Firefly partner model program that integrates third-party models including FLUX.1 from Black Forest Labs, giving users access to a broader range of generative styles within the familiar Creative Cloud interface.\n\nFirefly is integrated into Photoshop, Illustrator, Express, and Premiere Pro, making it available to Adobe's 30M+ Creative Cloud subscribers without additional purchase. Enterprise licenses include access to custom-trained Firefly models fine-tuned on brand assets, enabling consistent brand identity across AI-generated content. As the market leader in professional creative tools, Adobe's position gives Firefly a distribution advantage that standalone generative AI tools cannot easily replicate.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.